3Adler DD, Carson PL, Rubin JM, et al. Doppler ultra-sound color flow imaging in the study of breast cancer: preliminary findings[J]. Ultrasound Med Biol, 1990, 16(6):553-558.
6Bedrosian I, Bedi D, Kuerer HM, eta]. Impact of elinieopath- ologieal factors on sensitivity of axillary utrasonography in detection of axillary nodal metastases in patients with breast cancer[J]. Ann Surg Oncol, 2003, 10(q): 1025-1030.
7ChoiYJ, Ko EY, Han BK, et al. High-resolution ultrasono- graphic featm'es of axillary lymph node metastasis in patients with breast cancer[J]. Breast, 2009, 18(2): 119-122.
8BediDG, Krishnamurthy ]R, Krishnamurthy S, et al. Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study[J]. Am J Roentgen , 2008, 191 (3):646-652.
8Baker RR. Preoperative assessment of the patient with breast cancer. Surg Clin North Am, 2002, 64(6): 1039- 1050.
9Bedrosian I, Bedi D, Kuerer HM, et al.lmpact of clinicopathological factors on sensitivity of axillary utrasonography in detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol, 2003, 10(9): 1025-1030.
10Adler D D, Carson P L, Rubin J M, et al.Doppler ultrasound color flow imaging in the study of breast cancer: preliminary findings. Ultrasound Med Biol, 1990, 16(6): 553-558.
3Gianni L, Pienkowski T, Im Y H, et al. Efficacy and safety ofneoadjuvant pertuzumab and trastuzumab in women with locally advanced inflammatory or early HER2-positive breast cancer (NeoSphere) : arandomised multicentre open-label phase 2 trial [ J ]. Lancet Oncol, 2012,13 ( 1 ) :25-32.
4Gianni L, Eiermann W J, Semiglazov V, et al. Neoad ju-vant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone in patients with HER2-positive locally advanced breast canc- er(the NOAH trial) :A randomised controlled superiority trial with aparallel HER2-uegative cohort [ J ]. Lancet, 2010,15(6) :375-377.
5Lari S A, Kuerer H M. Biological markers in DCIS and risk of breast recurrence: a systematic review[ J]. Cancer 2011,2( 1 ) :232-261.
6Albonico G, Querzoli P, Ferretti S, et al. Biological pro- file of in situ breast cancer investigated by immunohisto- chemical technique [ J]. Cancer Detect Prey, 1998,22 (4) :313-318.
7Elledge R M, Allred D C. The p53 tumor suppressor gene in breast cancer[ J]. Breast Cancer Res Treatment , 1994,32( 1 ) :39-47.
